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Abstract
Background: Antibodies to chromatin and soluble liver antigen have been associated with severe
form of autoimmune hepatitis and/or poor treatment response and may provide guidance in
defining subsets of patients with different disease behaviors. The major clinical limitation of these
antibodies is their lower individual occurrence in patients with autoimmune hepatitis.
Aim: To estimate the value of detection of these non-standard antibodies in autoimmune hepatitis
as prognostic markers.
Methods: Both antibodies were tested by enzyme immunoassay in 20 patients with autoimmune
hepatitis.
Results: Antibodies to soluble liver antigen were not detected in any of our patients. On the other
hand anti chromatin antibodies were present in 50% (10/20). Antibodies to chromatin occurred
more commonly in females than males (8/14 versus 2/6). Of the 14 patients who relapsed 8(57%)
had antichromatin antibodies while they were present in only 2 out of 6(33.3%) non relapsers.
Antichromatin antibodies were found more in patients with antinuclear (3/4) and anti smooth
muscle antibodies (9/13) more than in those with liver kidney microsomal antibodies (1/4) and
those seronegative (1/4) i.e. they were +ve in patients with type I (8/12(66.6%)) more than those
with type II (1/4(25%)) and those seronegative (1/4(25%)). Antibodies to chromatin are associated
with high levels of γ globulin but yet with no statistical difference between seropositive and
seronegative counterparts (p = 0.65).
Conclusion: Antibodies to chromatin may be superior than those to soluble liver antigen in
predicting relapse and may be useful as prognostic marker. Further studies with larger number of
patients and combined testing of more than one antibody will improve the performance parameters
of these antibodies and define optimal testing conditions for them before they can be incorporated
into management algorithms that project prognosis.
Published: 20 July 2009
Italian Journal of Pediatrics 2009, 35:22 doi:10.1186/1824-7288-35-22
Received: 16 May 2009
Accepted: 20 July 2009
This article is available from: http://www.ijponline.net/content/35/1/22
© 2009 El- Din Elshazly et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Italian Journal of Pediatrics 2009, 35:22 http://www.ijponline.net/content/35/1/22
Page 2 of 7
(page number not for citation purposes)
Introduction
Autoimmune hepatitis (AIH) is a progressive inflamma-
tory liver disorder preferentially affecting females and
characterized serologically by high amino-transferase lev-
els, elevated immunoglobulin G (IgG), and presence of
auto antibodies and histologically by interface hepatitis in
the absence of a known etiology[1].
Auto immune hepatitis is divided into two types accord-
ing to the auto antibody profile: Patients with type I are
positive for antinuclear antibody (ANA) and/or anti-
smooth muscle antibody (ASMA), patients with type 2 are
positive for anti-liver-kidney-microsomal antibody type 1
(Anti-LKM-1). So, anti-nuclear antibodies (ANA), anti-
smooth muscle antibodies (SMA) and anti-bodies to liver
kidney microsome type (1) are the conventional markers
of the disease, and each has been ascribed diagnostic sig-
nificance, when present in the appropriate clinical con-
text[2].
These diagnostic instruments lack prognostic value, and
new auto antibodies continue to be characterized in the
hope of defining pertinent target auto antigens and mark-
ers reflective of treatment outcome [3].
Anti-bodies to soluble liver antigen/liver pancreas (Anti-
SLA/LP), actin (anti-actin), chromatin (anti-chromatin)
and liver cytosol type 1 (anti-LC1) have been associated
with severe disease and/or poor treatment response. They
constitute non-standard markers of auto immune hepati-
tis, and they may provide guidance in-defining subsets of
patients with different disease behaviors [4].
Anti-SLA/LP has been associated with severe disease and
propensity to relapse after corticosteroid withdrawal [5].
Anti-actin identifies patients with a higher frequency of
treatment failure and death from liver failure or require-
ment for liver transplantation than sero-negative patients
[6].
Anti-chromatin are associated with higher serum levels of
γ globulin and immunoglobulin G and greater occurrence
of relapse after drug withdrawal [4].
With this background, we aimed in this study to estimate
the value of detection of non-standard antibodies namely
antichromatin and anti SLA in auto immune hepatitis as
prognostic markers in children.
Subjects and methods
This work included 20 children with autoimmune hepati-
tis recruited from the Hepatology Specialized Clinic, Chil-
dren's Hospital, Ain Shams University, and from Professor
Yassin Abd El-Ghaffar Charity Centre for the liver disease
and research, during the period from April to October
2008.
They were 14 (70%) females and 6(30%) males, their ages
ranged from 3 to 19 years with a mean of 9.25 years ±
4.12.
The diagnosis of auto-immune hepatitis was based on the
International Scoring Criteria for auto-immune hepati-
tis[7].
All the patients included were subjected to proper history
taking laying stress on age at diagnosis, the duration of
treatment, presenting symptoms as abdominal disten-
sion, jaundice, lower limb oedema, bleeding, hepatic
coma; thorough clinical examination laying stress on the
presence of jaundice, lower limb edema, abdominal
examination for hepatosplenomegaly and ascitis.
The laboratory investigations done included complete
blood count, serum ALT, AST, total bilirubin, direct
bilirubin, prothrombin time, serum albumin, serum pro-
tein electrophoresis, measurement of anti-chromatin anti-
bodies and anti-soluble liver antigen antibodies for all the
patients. Abdominal ultrasound was done for all the
patients and liver biopsy was done for 11 patients.
Three ml of blood was withdrawn from each patient, left
to clot in a test tube. Tubes were then centrifuged and the
resulting serum was separated into an aliquots. Aliquots
were preserved at -20°c, till they were subsequently
assayed.
Antichromatin antibodies were measured using an
enzyme-linked immunosorbent assay kit, a product of
QUANTA lite™*. The assay depends on a highly purified
calf thymus consisting of DNA wrapped around the core
histone octamer. The chromatin is bound to the wells of a
microwell plate.
Anti-soluble liver antigen antibodies were measured using
an enzyme linked immunosorbent assay kit, a product of
Quanta lite™*. The assay depends on partially purified,
full-length recombinant human SLA antigen which
bound to the wells of polystyrene microwell plate under
conditions that will preserve the antigen in its nature state.
Both assays were evaluated spectrophotometrically by
measuring and comparing the color intensity that devel-
ops in the patient wells with the color in the control wells.
Samples were interpreted as negative, equivocal, or posi-
tive according to the following cut off values:
Negative 0.0–20.0 unitsItalian Journal of Pediatrics 2009, 35:22 http://www.ijponline.net/content/35/1/22
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Equivocal 20.1–24.9 units
Positive ≥ 25 units
Statistical analysis
The data were coded, entered and processed on an IBM-
PC compatible computer using SPSS (version 15). The
level P < 0.05 was considered the cut-off value for signifi-
cance. Student's t-test was used to compare the children
with positive Anti-Chromatin and those without regard-
ing sex, standard antibodies, number of relapses, liver
enzymes and gamma globulin level.
Results
Clinical data of our children showed that hepatomegaly,
splenomegaly and ascitis were present in 90, 70 and 10
percent respectively, eighty five percent of our children
presented by jaundice and only one case presented by
edema of lower limbs while none of them have other
autoimmune diseases (table 1). ANA were found to be
positive in 4 patients, two of them have ASMA also posi-
tive, and the other two have both ASMA and anti- LKM
antibodies positive. ASMA were found in 13 patients, two
of those patients have ANA positive, and another two of
the 13 patients have both ANA and anti- LKM antibodies
positive. Anti- LKM antibodies were positive in 5 patients,
2 two of them have both ASMA and ANA positive. Liver
biopsy done in eleven children revealed interface hepatitis
in all of them, cirrhosis in 27% (3/11) and fibrosis in 54%
(6/11) (table 2). Gamma globulin level at presentation
was ranging from 1.76–6.07 g/dl with a mean of 3.2 g/dl;
forty five percent of our children have gamma globulin
level equal to or exceeding 3.3 g/dl.
Antibodies to chromatin were detected in 50% of our chil-
dren with a mean of 39.85 ± 29.47; on the other hand
none of the patients have anti- SLA antibodies (table 3).
Comparing between patients with antichromatin anti-
bodies and those without, these antibodies were detected
more commonly in females but not reaching a statistical
significant difference (p = 0.63). Also antichromatin anti-
bodies were found more in patients with ANA (3/4) i.e.
75% but not reaching statistical significant difference (p =
0.264), and ASMA (9/13) i.e. 69% with statistical signifi-
cance difference (p = 0.019), more than in those with LKM
antibodies (2/5) i.e., 40%, and those seronegative (1/4)
i.e. 25%. Of the 14 patients who relapsed during therapy,
8(57%) had anti-chromatin antibodies with statistical sig-
nificant difference (p = 0.040) (table 4). Six out of the 8
patients (75%) with antichromatin antibodies who
relapsed during treatment have 4 or more relapses, while
the other 2 have two or three relapses.
There was no statistical significant difference between
patients with anti-chromatin antibodies and those with-
out regarding the laboratory findings, except for transam-
inases level at presentation, where their level were lower
Table 1: Clinical data of the studied patients with auto-immune 
hepatitis at presentation (n = 20).
Age 9.25 ± 4.12 (3–19)
Mean ± SD (range) years
No %
1) Sex (M/F) 6/14 30/70
2) Abdominal examination
a) Hepatomegaly 18 90
b) Splenomegaly 14 70
c) Ascitis 2 10
3) Jaundice 17 85
4) Oedema of L.L. 15
5) Other auto-immune diseases 00
Table 2: Diagnostic antibodies of auto-immune hepatitis in our 
children (n = 20) and results of liver biopsy in 11 patients.
No %
Diagnostic antibodies
1) ANA +ve: 4 20
2) ASMA +ve: 13 65
3) Anti-LKM +ve: 5 25
Liver biopsy
1) Interface hepatitis 11/11 100
2) Cirrhosis 3/11 27
3) Fibrosis 6/11 54
Table 3: Non-standard antibodies anti-chromatin, anti-SLA 
among our patients (n = 20).
Mean ± SD Range +ve (n/%)
Anti-chromatin 39.85 ± 29.47 (20–140) 10(50%)
Anti-SLA 2.16 ± 1.4 (0.06–5.5) 0(0%)Italian Journal of Pediatrics 2009, 35:22 http://www.ijponline.net/content/35/1/22
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in children with anti-chromatin antibodies than those
seronegative (p = 0.032 and 0.041), regarding gamma
globulin level eight out of the nine patients with gamma
globulin more than or equal to 3.3 gm/dl have antichro-
matin antibodies with statistical significant correlation (p
= 0.02) (table 5).
Discussion
Autoimmune hepatitis is a progressive inflammation of
the liver of unknown cause. It is characterized by the pres-
ence of interface hepatitis on histological examination,
hypergammaglobulinemia and auto-antibodies. There are
no features that are absolutely diagnostic, and the exist-
ence of the condition can be established only by recogni-
tion of a constellation of compatible features and the
exclusion of other diseases[2].
The laboratory features of autoimmune hepatitis reflect its
hepatic and immune nature. The predominant abnormal-
ities are elevated serum aminotransaminases levels, which
can mimic a severe acute hepatitis. Most patients have
substantial increases in the serum gamma-globulin and
immunoglobulin G levels. Strong cholestatic features,
mainly serum alkaline phosphatase levels that exceed 2-
fold the upper limit of normal discourage the diagnosis,
only 21% of patients have serum alkaline phosphatase
levels that exceed 2-fold normal, and none with classical
disease have serum alkaline phosphatase levels that
exceed 4-fold normal[8].
Table 4: Comparison between patients with anti chromatin antibodies and those without regarding sex of our patients, other auto-
antibodies, and number of relapses (n = 20).
Anti-chromatin
No. of cases 10 cases were +ve 10 cases were -ve P Sig.
1) Sex
F/M 8/2 6/4 0.63 NS
2) Antibodies
1-ANA (+ve) 4 3 1 0.264 NS
2-ASMA (+ve) 13 9 4 0.019 S
3-Ani-LKM (+ve) 5 2 3 0.606 NS
4-Seronegative 4 1 3 0.61 NS
3) Relapses 14 8 6 0.040 S
Table 5: Comparison between patients with anti chromatin antibodies and those without regarding liver enzymes and gamma globulin 
level at presentation (n = 20).
Anti-chromatin
No. of cases 10(50%) +ve 10(50%) -ve P Sig.
Liver enzymes
ALT (XN) mean 20 6N 12N 0.032 S
AST (XN) mean 20 5N 11N 0.041 S
Gamma globulin (g/dl)
≤ 3.3 11(55%) 2 9 0.02 S
≥ 3.3 9(45%) 8 1Italian Journal of Pediatrics 2009, 35:22 http://www.ijponline.net/content/35/1/22
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Smooth muscle antibodies, antinuclear antibodies, and
antibodies to liver kidney micorsome type 1 constitute the
conventional battery of serologic markers for autoim-
mune hepatitis. None of these antibodies is pathogno-
monic for the disease or diagnostic of the condition; their
presence supports the need for further diagnostic testing
[9].
Non standard autoantibodies are still being evaluated as
diagnostic and prognostic indices and have not been for-
mally incorporated into clinical algorithms. Nevertheless,
they have the promise of enhancing diagnostic specificity
and adding a prognostic dimension to the serologic pro-
file. Perinuclear antineutrophil cytoplasmic antibodies
may be useful in classifying patients who lack the conven-
tional serologic markers, and IgA antibodies to
endomysin may identify individuals with celiac-related
liver disease. Antibodies to soluble liver antigen/liver pan-
creas, actin, chromatin, asialoglycoprotein receptor and
liver cytosol type 1 have been associated with severe dis-
ease or poor treatment response, and some autoantibod-
ies may be reflective of genetic propensities that affect
outcome[10].
Antibodies to soluble liver antigen/liver pancreas and
actin have been associated with human leukocyte antigen
DR3, and there may be other serologic expressions with a
similar genetic association that augur a poor prognosis.
The major clinical limitation of the non-standard anti-
bodies has been their low individual occurrence in
patients with autoimmune hepatitis[11].
The aim of this study is to evaluate the performance
parameters of these non-standard autoantibodies, espe-
cially antichromatin and anti soluble liver antigen/liver
pancreases, as prognostic markers in children with
autoimmune hepatitis.
Autoimmune liver disease has been described to have a
female predominance; this ratio is about 4:1 in some
reports.
In our study the overall female/male ratio was 2.3:1, this
goes hand in hand with [12], who found that autoim-
mune hepatitis affects all ages with a peak incidence in
preadolescent girls and that women are affected more
than men with gender ratio 3.6:1.
In a study by [13] reviewing 20 years experience in
autoimmune hepatitis in children they showed that type I
autoimmune hepatitis represents two thirds of the cases.
In our patients type I showed an increasing incidence 11/
20 versus 5/20 with type II autoimmune hepatitis. Also in
a study by [14], they found that 73.3% (22/30) children
had type I autoimmune hepatitis versus 13.3% (4/30) had
type II. Similar findings were found by [15], who carried
their study on 60 Iranian children to evaluate their clinical
and para-clinical presentation, and found that 40(60%)
children have type I autoimmune hepatitis and 14(23%)
had type II autoimmune hepatitis.
In accordance with previous studies there were no partic-
ular clinical signs, symptoms, or liver test abnormalities of
sufficient specificity to be considered as a reliable part of
diagnostic criteria[7]. Like our patients (85%), in four
independent studies 60%, 63%, 56% and 57.7% of
reported patients had jaundice at presentation. In [16]
study, the majority of their patients (82%) had hepatome-
galy and splenomegaly (74%) at presentation which is
very similar to our children where 90% (18/20) of them
presented by hepatomegaly and 70% (14/20) had
splenomegaly. The same was found by [17] in his study
on the diagnostic criteria, subclassification and clinical
features of autoimmune hepatitis, where a large percent-
age of his patients presented by hepatosplenomegaly.
Autoimmune hepatitis has associations with other
autoimmune disorders [18]. In the present study, we did
not find any evidence of associated autoimmune diseases
especially the most common as thyroid disease, celiac dis-
ease and hemolytic anemia.
Autoimmune hepatitis is known to be a progressive
necroinflammatory liver disorder of unknown cause,
characterized by the presence of hyper gamma globuline-
mia[19]. Accordingly all our children have hypergamma-
globulinemia ranging from 1.76–6.07 g/dl with a mean of
3.2, 9/20 of our children (45%) have gammaglobulin
level ≥ 3.3 g/dl. Similarly in a study by [14], they found
that all their patients had elevated globulin concentration
probably as an indicator for an immunologically active
disease, with 73.3% of their children have significant
titres (>3).
The characteristic histological picture is interface (peripor-
tal or preseptal) hepatitis with lymphoplasmatic necro-
inflammatory infiltrate with or without lobular (intra-aci-
nar) involvement, porto-portal or central-portal bridging
necrosis with the formation of liver cell rosettes and a
great amount of plasma cells at an early stage of the dis-
ease[16]. Cirrhosis was reported in range of less than half
to more than 90% of affected children [20,21,16]. In our
study histological exploration of 11 children revealed
interface hepatitis in 100%, fibrosis in 54% (6/11) and
cirrhosis in 27% (3/11). The same was found by [22] who
detected that 36% (11/30) of their children with autoim-
mune hepatitis presented by cirrhosis on the initial biopsy
done prior to treatment.
Searching for non-standard antibodies in our children,
antichromatin antibodies were detected in 50% (10/20)
while none of them have anti-soluble liver antigen (anti-Italian Journal of Pediatrics 2009, 35:22 http://www.ijponline.net/content/35/1/22
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SLA) antibodies, same findings were in the study done by
[10] on 106 patients with autoimmune hepatitis where,
antibodies to actin (82%) and antichromatin (36%) were
the most commonly detected non-standard markers. In
contrast anti-SLA (16%) were infrequently detected. Also,
[23], when investigated anti-SLA autoantibodies in Japa-
nese patients with autoimmune liver diseases, they found
that these antibodies were detected in only 6.7% (5/75) of
patients with autoimmune hepatitis type 1.
Also [4] performed a study on 172 patients with autoim-
mune hepatitis to determine the frequency and prognostic
implications of antibodies to chromatin, they found that
39% (67/172) had antibodies to chromatin, which is near
to our percentage.
The mean level of anti-chromatin antibodies was higher
in our children with type I autoimmune hepatitis than in
type II or seronegative patients (58.83 ± 38.4, 29.8 ± 15.4
and 34.2 ± 21.48 respectively), yet not reaching a statisti-
cal significant difference (p = 0.038).
Previous studies have indicated that antichromatin are
more commonly present in men than women with
autoimmune hepatitis, 58% versus 34% in men and
women respectively[4], and 55% in males versus 31% in
females[10]. In contrast, our present study doesn't show
this tendency where anti-chromatin antibodies were
detected in 57% in females versus 33% in males. Gender
does influence the cytokine response to foreign and self
antigens, and the type 2 cytokine response which predom-
inates in men rather than women after antigen exposure
may facilitate plasma cell activation and the production of
anti-chromatin[24]. This was not the case in our study,
which may be related to the small number of children
included in this study.
Ninety percent (9/10) of serum samples from our chil-
dren with autoimmune hepatitis that are positive for anti-
chromatin also have other antibodies (antinuclear, antis-
mooth muscle or anti-liver kidney microsomal), but only
56% (9/16) of seropositive serum samples have anti-chro-
matin antibodies. [25] who found antichromatin in 53%
of Japanese patients with type 1 autoimmune hepatitis
also demonstrated that seropositivity for anti-chromatin
was not ablated by adsorption of sera with double-
stranded DNA and histones. These dissociations with
standard antibodies, double stranded DNA, and histones
in autoimmune hepatitis justify the evaluation of anti-
chromatin as a separate autoantibody of possible prog-
nostic importance.
In our study, antichromatin antibodies were detected
more in children with antinuclear (75%), and antismooth
muscle antibodies (69%) i.e., those with type I autoim-
mune hepatitis, more than those with anti-liver kidney
microsomal antibodies (40%), i.e., those with type II
autoimmune hepatitis.
The ten children with anti-chromatin antibodies 8 of
them were type I with a percentage 72% (8/11) of all
those categorized as type I, while the rest 2 children with
anti-chromatin antibodies were type II with a percentage
40% (2/5) of all those with type II autoimmune hepatitis.
The bases for the association of anti-chromatin and anti-
soluble liver antigen with relapse in autoimmune hepati-
tis are unknown. Chromatin is a macromolecular acta-
meric complex that has multiple epitopes, and it is a
powerful immunogen that has been implicated in the
autoimmunization associated with systemic lupus eryth-
romatosus[26].
Loss of tolerance to chromatin may promote production
of antibodies to diverse nuclear epitopes, including his-
tones and double stranded DNA. These multiple collateral
immune reactions may in turn be difficult to suppress or
eliminate with corticosteroids therapy, and they may
increase the liver injury by impairing critical nuclear func-
tions within the hepatocyte[10]. In a previous study by
[10] they found that among 74 patients who relapsed, 40
had antichromatin and/or anti-SLA (54%), and the fre-
quency of relapses was significantly higher in these
patients than in those without these markers (100% ver-
sus 79%). The same was found in our study where 8 out
of the 14 patients who relapsed during treatment (57%)
had antichromatin antibodies (p = 0.04). Also six out of
the eight relapsing patients (75%) with antichromatin
antibodies had 4 or more relapses during treatment, while
the other 2 had one or two relapses only, showing that the
presence of antichromatin antibodies is frequently associ-
ated with frequent relapsing.
The same was found by [4], where they detected that
relapse after drug withdrawal occurred more often in sero-
positive patients (91% versus 66%, p = 0.002), so they
concluded that seropositivity to chromatin can identify
individuals who commonly relapse after drug withdrawal.
Antibodies to chromatin had complete specificity for
relapse, in the study done by [10], the sensitivity for
detecting relapse was 42% for antichromatin and predict-
ability was 50%.
There was no statistical significant difference between
children with antichromatin antibodies and those with-
out regarding all laboratory data except for transaminases
levels and gamma globulin levels, where 88.8% (8/9) of
children with gamma-globulin ≥ 3.3 had antichromatin
antibodies (p = 0.02). The same was found by [25] whoItalian Journal of Pediatrics 2009, 35:22 http://www.ijponline.net/content/35/1/22
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assessed the frequency and significance of antibodies to
chromatin in 36 Japanese patients with autoimmune hep-
atitis type 1, and found that patients with antichromatin
antibodies had significantly high serum levels of gamma-
globulin and immunoglobulin G. Similarly [4]found that
their patients who were seropositive for antichromatin
antibodies had higher serum levels of gamma-globulin
and immunoglobulin G.
Regarding transaminases at presentation, a statistical sig-
nificant difference was found between children with anti-
chromatin antibodies and those without in the mean ALT
(6xN versus 12xN respectively) (p = 0.032) and mean AST
(5xN versus 11xN respectively) (p = 0.041). Where chil-
dren with +ve anti-chromatin antibodies have lower levels
of transaminases at presentation than those seronegative
children. This finding increases our awareness not to rely
on the degree of rise of transaminases in predicting the
outcome of the disease i.e., tendency to relapse, as the
children with +ve anti-chromatin antibodies and lower
levels of transaminases at presentation were more liable to
relapse than those without anti-chromatin antibodies.
In conclusion, antichromatin antibodies are associated
with higher incidence of relapse in autoimmune hepatitis,
and may be useful as prognostic marker. Efforts must con-
tinue to define optimal testing conditions for these non
standard antibodies before they can be incorporated into
management algorithms that project prognosis, and com-
bined testing of more than one antibody can improve
their sensitivity, predictability and durability.
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